The inflammatory microenvironment in colorectal neoplasia.
Colorectal cancer (CRC) is a major cause of mortality and morbidity worldwide. Inflammatory activity within the stroma of invasive colorectal tumours is known to be a key predictor of disease activity with type, density and location of immune cells impacting on patient prognosis. To date, there has been no report of inflammatory phenotype within pre-malignant human colonic adenomas. Assessing the stromal microenvironment and particularly, inflammatory activity within colorectal neoplastic lesions is central to understanding early colorectal carcinogenesis. Inflammatory cell infiltrate was assessed by immunohistochemistry in paired colonic adenoma and adjacent normal colonic mucosa samples, and adenomas exhibiting increasing degrees of epithelial cell dysplasia. Macrophage phenotype was assessed using double stain immunohistochemistry incorporating expression of an intracellular enzyme of function. A targeted array of inflammatory cytokine and receptor genes, validated by RT-PCR, was used to assess inflammatory gene expression. Inflammatory cell infiltrates are a key feature of sporadic adenomatous colonic polyps with increased macrophage, neutrophil and T cell (specifically helper and activated subsets) infiltration in adenomatous colonic polyps, that increases in association with characteristics of high malignant potential, namely, increasing degree of cell dysplasia and adenoma size. Macrophages within adenomas express iNOS, suggestive of a pro-inflammatory phenotype. Several inflammatory cytokine genes (CXCL1, CXCL2, CXCL3, CCL20, IL8, CCL23, CCL19, CCL21, CCL5) are dysregulated in adenomas. This study has provided evidence of increased inflammation within pre-malignant colonic adenomas. This may allow potential mechanistic pathways in the initiation and promotion of early colorectal carcinogenesis to be identified.
Gastrointestinal Research Group, School of Medicine and Dentistry, Aberdeen University, Aberdeen, United Kingdom.
Mairi H
MH
McLean
Graeme I
GI
Murray
Keith N
KN
Stewart
Gillian
G
Norrie
Claus
C
Mayer
Georgina L
GL
Hold
John
J
Thomson
Nicky
N
Fyfe
Mairi
M
Hope
N Ashley G
NA
Mowat
Janice E
JE
Drew
Emad M
EM
El-Omar
D000236:Adenoma / Q000235:genetics / Q000473:pathology; D003111:Colonic Polyps / Q000235:genetics / Q000473:pathology; D015179:Colorectal Neoplasms / Q000473:pathology*; D016207:Cytokines / Q000235:genetics; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D011230:Precancerous Conditions / Q000473:pathology*; D011379:Prognosis; D059016:Tumor Microenvironment
D016207:Cytokines
Clin Cancer Res. 2005 May 15;11(10):3758-65
15897573
Cancer Res. 2001 Apr 1;61(7):3124-30
11306497
Mol Cancer Res. 2007 Dec;5(12):1263-75
18171984
J Gastroenterol. 2006 Nov;41(11):1053-63
17160516
Cell. 2000 Oct 27;103(3):481-90
11081634
Tumour Biol. 2006;27(3):166-74
16641550
Res Commun Mol Pathol Pharmacol. 1997 Aug;97(2):229-32
9344234
N Engl J Med. 2003 Mar 6;348(10):883-90
12621132
Gastroenterology. 1992 Oct;103(4):1260-6
1397883
J Leukoc Biol. 2003 Feb;73(2):209-12
12554797
Cancer Res. 2007 Oct 15;67(20):9996-10003
17942933
Anticancer Res. 2005 Sep-Oct;25(5):3581-4
16101183
Exp Hematol. 2005 Oct;33(10):1101-8
16219532
Parasite Immunol. 2003 May;25(5):235-46
12969442
Pac Symp Biocomput. 2008;:166-77
18229684
Br J Cancer. 2008 Jan 29;98(2):426-33
18071363
Science. 2006 Sep 29;313(5795):1960-4
17008531
J Invest Dermatol. 1996 Aug;107(2):159-63
8757756
J Immunol. 1999 Oct 1;163(7):3771-7
10490974
Oncogene. 2002 Jun 13;21(26):4120-8
12037668
Gut. 2008 Jun;57(6):780-7
18272544
Histopathology. 2008 Jun;52(7):806-15
18462368
Toxicol Lett. 2004 Dec 30;154(3):175-82
15501609
Res Commun Mol Pathol Pharmacol. 1997 Oct;98(1):103-8
9434320
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5951-9
17062666
Histopathology. 2009 Jun;54(7):820-8
19635101
Cytokine. 2005 Jun 7;30(5):254-63
15927850
Cell. 1990 Jun 1;61(5):759-67
2188735
Clin Cancer Res. 2003 Aug 1;9(8):3167-75
12912969
Tumour Biol. 2010 Apr;31(2):89-96
20358421
Biochem Biophys Res Commun. 2002 Aug 16;296(2):497-506
12163047
Lancet. 2008 Mar 1;371(9614):771-83
18275997
Biochem Biophys Res Commun. 2006 Feb 10;340(2):498-504
16378600
J Exp Med. 1999 Feb 1;189(3):451-60
9927507
J Exp Med. 1996 Apr 1;183(4):1323-9
8666890
Lancet Oncol. 2004 Mar;5(3):182-90
15003202
Breast Cancer Res. 2007;9(4):212
17705880
Mol Cancer Ther. 2007 Nov;6(11):2948-58
18025279
J Clin Invest. 2010 Apr;120(4):1151-64
20237412
N Engl J Med. 1991 Dec 5;325(23):1593-6
1669840
Methods. 2001 Dec;25(4):402-8
11846609
Histochem Cell Biol. 2008 Dec;130(6):1091-103
18987874
J Exp Med. 2006 Apr 17;203(4):941-51
16567391
Br J Cancer. 1999 Oct;81(4):647-53
10574250
N Engl J Med. 2003 Mar 6;348(10):891-9
12621133
FEBS Lett. 1997 May 19;408(2):211-6
9187369
Int J Colorectal Dis. 2003 May;18(3):181-7
12673481
J Exp Med. 2001 Jan 15;193(2):207-18
11148224
Gastroenterology. 2003 Aug;125(2):328-36
12891533
Prostate. 2006 Feb 1;66(2):124-34
16161154